ProfileGDS5678 / 1432968_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 47% 44% 45% 43% 46% 43% 47% 49% 44% 44% 44% 45% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.095745
GSM967853U87-EV human glioblastoma xenograft - Control 23.1041247
GSM967854U87-EV human glioblastoma xenograft - Control 33.0349144
GSM967855U87-EV human glioblastoma xenograft - Control 42.9972545
GSM967856U87-EV human glioblastoma xenograft - Control 52.9459243
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1677446
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0702443
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1077447
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1587749
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0035244
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0256844
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9793844
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0524745
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3996856